Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin effects on cardiac structure and function in adults with type 2 diabetes
ACTRN12616001535460Phase 4Completed
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Baker Heart and Diabetes Institute. Primary endpoints: Left ventricular end-diastolic volume index, Left ventricular ejection fraction and 3 more. Started May 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12616001535460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001535460.